At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases.
The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more information, please visit soleno.life.
